On Tuesday, Mineralys Therapeutics Inc (NASDAQ: MLYS) opened higher 3.06% from the last session, before settling in for the closing price of $15.70. Price fluctuations for MLYS have ranged from $8.24 to $18.38 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 10.24% at the time writing. With a float of $40.49 million, this company’s outstanding shares have now reached $64.88 million.
The firm has a total of 51 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mineralys Therapeutics Inc (MLYS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Mineralys Therapeutics Inc is 37.88%, while institutional ownership is 65.21%. The most recent insider transaction that took place on May 14 ’25, was worth 173,774. In this transaction Chief Medical Officer of this company sold 11,366 shares at a rate of $15.29, taking the stock ownership to the 106,669 shares. Before that another transaction happened on May 14 ’25, when Company’s Officer proposed sale 11,366 for $15.29, making the entire transaction worth $173,774.
Mineralys Therapeutics Inc (MLYS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 10.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.33% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Check out the current performance indicators for Mineralys Therapeutics Inc (MLYS). In the past quarter, the stock posted a quick ratio of 26.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.74, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -3.34 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Analysing the last 5-days average volume posted by the [Mineralys Therapeutics Inc, MLYS], we can find that recorded value of 0.58 million was lower than the volume posted last year of 0.92 million. As of the previous 9 days, the stock’s Stochastic %D was 49.89%. Additionally, its Average True Range was 0.99.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 78.30%, which indicates a significant increase from 68.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.62% in the past 14 days, which was lower than the 95.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.62, while its 200-day Moving Average is $12.68. Now, the first resistance to watch is $16.45. This is followed by the second major resistance level at $16.72. The third major resistance level sits at $17.20. If the price goes on to break the first support level at $15.70, it is likely to go to the next support level at $15.22. Should the price break the second support level, the third support level stands at $14.95.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
There are currently 65,175K shares outstanding in the company with a market cap of 1.05 billion. Presently, the company’s annual sales total 0 K according to its annual income of -177,810 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -42,210 K.
